Lipid profile status and other related factors in patients with Hyperphenylalaninaemia

María L. Couce 1*, Isidro Vitoria 2, Luis Aldamiz-Echevarría 3, Ana Fernández-Marmiesse 1, Iria Roca 1, Marta Llarena 3, Paula Sánchez-Pintos 1, Rosaura Leis 4 and Alvaro Hermida 5

Abstract

Background: The mainstay of treating patients with phenylketonuria (PKU) is based on a Phe-restricted diet, restrictive in natural protein combined with Phe-free L-amino acid supplements and low protein foods. This PKU diet seems to reduce atherogenesis and confer protection against cardiovascular diseases but the results from the few published studies have been inconclusive. The aim of our study was to evaluate the relationship between the lipid profile and several treatment-related risk factors in patients with hyperphenylalaninaemia (HPA) in order to optimize their monitoring.

Methods: We conducted a cross-sectional multicentre study. A total of 141 patients with HPA were classified according to age, phenotype, type of treatment and dietary adherence. Annual median blood phenylalanine (Phe) levels, Phe tolerance, anthropometric measurements, blood pressure (BP) and biochemical parameters (triglycerides, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), apolipoprotein A (ApoA), apolipoprotein B (ApoB), vitamin B12, total homocysteine (tHcy), Methionine (Met), high sensitivity C-Reactive Protein (hsCRP)) were collected for each patient.

Results: Plasma TC levels were lower in patients with PKU than in the mild-HPA group (150 ± 31 vs. 164 ± 22 mg/dL), and there was a weak inverse correlation between plasma TC and Phe levels. HDL-C, LDL-C, ApoA and ApoB levels were lower in the PKU group than in mild-HPA. Patients with PKU had higher systolic BP than the mild-HPA group and there was found a quadratic correlation between median Phe levels and systolic BP (p = 6.42e^{-5}) and a linear correlation between median Phe levels and diastolic BP (p = 5.65e^{-4}). In overweight or obese PKU patients (24.11%), biochemical parameters such as TC, triglycerides, LDL-C, tHcy, hsCRP and BP were higher. By contrast, HDL-C was lower in these patients.

Conclusion: Our data show a direct correlation between lipid profile parameters and good adherence to the diet in PKU patients. However, lipid profile in overweight or obese patients displayed an atherogenic profile, in addition to higher hsCRP concentrations and BP. Our study contributes to a better understanding of the relationship between phenotype and treatment in patients with HPA, which could be useful in improving follow-up strategies and clinical outcome.

(Continued on next page)
Trial registration: Research Ethics Committee of Santiago-Lugo 2015/393. Registered 22 September 2015, retrospectively registered.

Keywords: Atherogenic profile, Blood pressure, Coronary heart disease, Homocysteine, Lipoprotein, Phenylketonuric dietary treatment

Abbreviations: 6R-BH4, (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin; AC, Mid-upper arm circumference; ApoA, Apolipoprotein A; ApoB, Apolipoprotein B; B12, Vitamin B12; BMI, Body mass index; BP, Blood pressure; CPKU, Classic PKU; Cu, Copper; DBP, Diastolic BP; tHcy, Total homocysteine; HDL-C, High-density lipoprotein cholesterol; HPA, Hyperphenylalaninaemia; hsCRP, High sensitivity C-Reactive Protein; LDL-C, Low density lipoprotein-cholesterol; Met, Methionine; MHPA, Mild-hyperphenylalaninaemia; MPKU, Mild-moderate PKU; Phe, Phenylalanine; PKU, Phenylketonuria; SBP, Systolic BP; TC, Total cholesterol; TGC, Triglycerides; WC, Waist circumference; Zn, Zinc

Background
Phenylketonuria (PKU; MIM 261600), an autosomal recessive disorder of Phenylalanine (Phe) metabolism, is mainly caused (98 % of cases) by deficient activity of the hepatic enzyme L-phenylalanine-4-hydroxylase (PAH; EC 1.14.16.1), due to mutations in the PAH gene (NM 000277.1). Loss of PAH activity results in increased blood Phe concentrations which leads to irreversible neurological damage if it is untreated. Average incidence in Caucasians is of 1 in 10,000 individuals [1]. Hyperphenylalaninaemia (HPA) is usually diagnosed by Newborn Screening Programme, routinely performed in Spain since 1980 [2], which enable early diagnosis and treatment. Pre-established thresholds for plasma Phe concentrations according to age are not yet standardized and vary among countries [3, 4].

Despite the appearance of novel approved treatment approaches (for example, large neutral amino acids, (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (6R-BH4) and glycomacropeptide), dietary intervention remains the mainstay of treating patients with PKU [5]. Patients are typically recommended to follow a PKU diet based on low Phe intake. This diet consists of a marked reduction in natural protein, with supplementation with Phe-free amino acid mixture.

There is a general agreement that patients with PKU require long-term dietary counselling as well as daily nutritional supplementation [5]. This diet has some drawbacks, such as the poor organoleptic properties (taste, scent) of the Phe-free protein substitutes and special-manufactured low-protein foods which are likely to have a negative effect on compliance with the diet. Furthermore, long-term safety of this dietary treatment as well as its potential association with risk of non-communicable diseases in later stages should be further investigated [6]. In this regard, there are several recently published reports about the contribution of mineral and vitamin status [7–11]. However, very few studies have explored the blood lipid profile in PKU [12, 13]. In particular, it has been observed that PKU children who had good adherence to diet, consumed saturated (below 7 %) and polyunsaturated (above 5 %) fats from total daily energy with amounts below 50 mg of cholesterol per day [14].

The aim of our study was to determine the blood lipid profile status and several cardiovascular-related risk factors, such as overweight/obesity, plasma total homocysteine (tHcy) levels, high-sensitivity C-reactive protein (hsCRP), micronutrients (zinc (Zn) and cupper (Cu)) and blood pressure (BP) in patients with PKU, who were classified into groups according to Phe tolerance, 6R-BH4 supplementation and adherence to diet. Moreover, we further analysed potential risk factors due to its deficiency or over supplementation.

Methods
Study design
A total of 141 patients were enrolled in this cross-sectional multicentre study between February 2015 and February 2016 from three Metabolic Diseases Unit at three Spanish Hospitals: Hospital Universitario La Fe (Valencia) (n = 62), Hospital Universitario Cruces (Basque Country) (n = 23) and Hospital Clínico Universitario de Santiago (Galicia) (n = 56). The study protocol was approved by the Research Ethics Committee of Santiago-Lugo (2015/393). Written informed consent was obtained from parents or legal guardians of children (below 16 years of age) and patients included. Patients were followed in their respective Centre from the date of diagnosis up to current date. The study included both patients who were diagnosed through Newborn Screening Programmes as well as patients who were later diagnosed due to the appearance of clinical symptoms. Exclusion criteria were: (1) poor medical monitoring, changes in amino acid mixture during the month prior to enrolment and (3) pregnancy.
Data collected for each patient were: age, gender, phenotype [patients were classified into phenotypic categories according to blood Phe levels, which were measured at diagnosis, based on US Guidelines [15]: mild-hyperphenylalaninaemia (MHPA), (120–360 μmol/L); mild-moderate PKU (MPKU), (360–1200 μmol/L) and classic PKU (CPKU), (>1200 μmol/L)], diagnosis time (early versus late diagnosis), annual median blood Phe levels (pre-established “safe” thresholds: <360 μmol/L for children below 6 years of age; <480 μmol/L for those from 6 to ≤10 years of age and ≤600 μmol/L for those >10 years of age) [2], anthropometric characteristics [weight, height, body mass index (BMI), waist circumference (WC) and mid-upper arm circumference (AC)], Phe levels (pre-established “safe” thresholds: <360 μmol/L for children below 6 years of age; <480 μmol/L for those from 6 to ≤10 years of age and ≤600 μmol/L for those >10 years of age) [2], nutritional characteristics [weight, height, body mass index (BMI), waist circumference (WC) and mid-upper arm circumference (AC)], Phe tolerance (low <500 mg/day, high >500 mg/day), 6R-BH₄ therapy (treated vs. non-treated), systolic and diastolic blood pressure (SBP and DBP), and blood biochemical measurements such as: triglycerides (TGC), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), apolipoprotein A (ApoA), apolipoprotein B (ApoB), Zn, Cu, vitamin B₁₂ (B₁₂), total homocysteine (tHcy), Methionine (Met). LDL cholesterol/ApoB and Zn/Cu ratios were calculated. High-sensitivity C-Reactive Protein (hsCRP) was measured in 55 patients. Blood samples for the measurements were obtained after overnight fasting at the same time (8:00 h in the morning) from patients without acute infection or medication (except from patients on 6R-BH₄ therapy). Reference range values (valid for all ages) for micronutrients were: vitamin B₁₂ (180-1900 pg/mL); Zn (65–140 μg/dL); Cu (65-140 μg/dL); tHcy (5-15 μmol/L); hsCRP (0-1.1 mg/dL) and Met (10-60 μmol/L) for patients <18 years of age; 20-37 μmol/L for patients >18 years of age). With regard to cardiovascular parameters the upper thresholds were: TC > 200 mg/dL, LDL-C > 130 mg/dL; ApoB ≥ 110 mg/dL and TGC > 100 mg/dL for patients from 0 to 9 years of age and >130 mg/dL for patients >10 years of age. Lower thresholds were: TGC < 30 mg/dL; HDL-C < 40 mg/dL and ApoA < 115 mg/dL. Adherence to treatment in patients with PKU was established according to their metabolic control by annual median blood Phe levels and the pre-established “safe” thresholds for each age (as above mentioned) [2]. Definition and staging of the metabolic syndrome (MS) was based on the 2007 World Health Organization (WHO) criteria: Central obesity (≥80 cm for men and ≥88 cm for women), combined with at least two of the following: high blood pressure (≥130/≥85 mmHg), high TC (≥150 mg/dL), high TGC (≥150 mg/dL), low HDL-C (<40 mg/dL for men and <50 mg/dL for women), and hypertriglyceridemia (≥150 mg/dL). The three Centres followed the same protocol. Dietary treatment was based on recommendations in the Spanish Guidelines for treating and monitoring patients with PKU [2]. That is, patients are typically recommended to follow a PKU diet, which consists of a marked reduction in natural protein diet, and supplementation with Phe-free amino acids mixture. Average protein intake was 1.3–1.5 times above Recommended Dietary Allowances (RDA) [18]. Nutritional diet was weekly assessed by 3-day food surveys completed using software www.odimet.es. The group of MHPA patients, who had Phe levels at diagnosis of 120-360 μM/L, did not require treatment and therefore they followed a normal diet.

Recumbent length was measured with a measuring board and weight with a manual baby scale until the age of 24 months. Thereafter, standing height was measured with a wall-mounted stadiometer and body weight, with digital scales. Patients were weighed barefoot and after overnight fasting. The nutritional status was assessed by calculating the body mass index (BMI) using the formula BMI = weight (kg) /height² (m²). Patients above 18 years of age were classified based on World Health Organization (WHO) criteria as: underweight (BMI <18.5), normal weight (BMI 18.5-24.99), overweight (BMI 25-29.99), and obese (BMI ≥30). Patients below 18 years of age were classified according to BMI using the WHO Child Growth Standards (Underweight: BMI below the 15th percentile; Normal: BMI from the 15th to 85th percentiles, Overweight: BMI from the 85th to 95th percentiles, Obese: BMI above the 95th percentile) [19, 20].

Waist circumference (WC) was measured at a level midway between the lower rib margin and the iliac crest and mid-upper arm circumference (AC) was measured at a point half-way between the elbow and the shoulder. These measurements (expressed in cm) were stratified according to gender and age based on the previously published study in children named Estudio Galinut [21]. In adult patients, specific values for WC and AC were used from the International Diabetes Federation (IDF) [22] and Frisancho’s study [23], respectively.

Phe levels from dried blood spots and plasma samples were measured using Tandem mass-spectrometry. TC, HDL-C and TGC concentrations were determined by standard procedures using an Advia 2400 Analyzer (Siemens Diagnostic Systems, Germany). When TGC levels were <350 mg/dL, LDL-C was estimated using the Friedewald formula LDL = TC - HDL-C - TG/5.0 (mg/dL). When TGC levels were >350 mg/dL, LDL-C was estimated by a direct method which was based on cholesterol oxidase, esterase and peroxidase, once lipoprotein cholesterol (other than LDL) were removed using an Advia 2400 Analyzer (Siemens Diagnostic Systems, Germany). Vitamin B₁₂ was determined using
an Advia Centaur XP Analyzer (Siemens Healthcare Diagnostics, Erlangen, Germany). Zn and Cu using a 7700 ICP-Mass Spectrometry System (Agilent, CA, USA). Plasma ApoA and ApoB levels were measured by immunonephelometry assay using a Dimension Vista™ 1500 Analyzer (Siemens Healthcare Diagnostics) and tHcy concentrations were determined in EDTA-plasma samples by a competitive immunoassay using an IMMULITE® 2000 Analyzer (Siemens Healthcare Diagnostics). hsCRP levels were determined by spectrophotometry.

BP was measured using an oscillometric device (Omron IT-750; Omron Healthcare, Tokyo, Japan) and an appropriate cuff was applied in the supine position after a resting period of 5 min. Patients were asked not to practice any physical activity and to avoid caffeinated beverages prior to medical appointments. Simultaneous supine measurements at both arms were recorded, and shortly afterward three additional supine measurements were taken at the arm with displayed the higher BP. Average of the last two measurements was used for data analysis.

Statistical test
In order to determine significant associations and/or differences between the different variables measured, the following methods were applied: first of all, we used the Kolmogorov–Smirnov and the Shapiro–Wilk tests to determine if the groups follow a normal distribution. Later, if one of the variables was quantitative and the other qualitative, we applied the Student t-test or the ANOVA if the quantitative variable was normal, and the Wilcoxon signed-rank or the Kruskal–Wallis test otherwise. If both variables were quantitative, under normality assumptions we fitted a linear regression model, and the p-value is the significance level of the adjustment; if the data wasn’t normal, we used the Kruskal–Wallis test. In the case that both variables were qualitative we used Fisher’s exact test. Finally, we adjusted the obtained p-values using the Benjamini–Hochberg correction. Only adjusted p-values lower than 0.05 were considered significant. Statistical analysis was performed using R Core Team [24], version 3.2.3.

Results
Our study included 141 patients with HPA [67 (47.5 %) males; range age: 6 months-50 years; mean age: 15 years 6 months]. There were 100 patients (71 % of our population) who were diagnosed with PKU and 41 (29 %) with MHPA. In the group of patients with PKU, 66 (66 %) were classified as CPKU and 34 (34 %) as MPKU. A total of 16 (11.3 %) of our patients were diagnosed at a later stage by the appearance of clinical symptoms, due to the fact that in Spain the Newborn Screening Program for PKU started in the 70-80’s. With regard to 6R-BH4 therapy, 17 (17 %) of the patients with PKU were treated, out of them 14 (82.3 %) were classified as MPKU.

Over the observation period, adequate dietary adherence was observed in 120 patients (85.1 % of our population); in the group of patients below 10 years of age (63), 56 (88.9 %) had adequate dietary adherence; whereas in the group of patients above 10 years of age (78), 14 (18 %) had low dietary adherence,13 (92.8 %) of these patients were above 18 years of age [5 (62.5 %) of them diagnosed at a later stage]. Only 1 (5.9 %) out of the 17 patients who were on 6R-BH4 treatment displayed Phe levels slightly above the pre-established “safe” threshold for their age ((P.23 Table 1 and Additional file 1).

With regard to blood lipid profile, TGC deficiency was observed in only 2 patients (1.4 %), but it was at the upper threshold in 26 patients (18.4 %), none of them was on 6R-BH4 treatment. Nevertheless, TC was decreased in 19 patients (13.5 %) (100 % of them were patients with PKU), out of them 14 (73.7 %) were below 18 years of age and 16 (84.2 %) of them had an adequate adherence to treatment. Similarly, HDL-C, LDL-C, ApoA and ApoB concentrations were below the low threshold in the PKU group compared with the MHPA group (Table 2, Fig. 1). However, in the group of PKU patients, those who had a good metabolic control displayed higher HDL-C concentrations and LDL/ApoB ratio than those with poor metabolic control (50.4 ± 12.02 vs. 47.4 ± 11.26 mg/dL and 1.22 ± 0.19 vs. 1.20 ± 0.23, respectively); although these differences did not reach statistical significance.

B12 levels were in the normal range or even slightly elevated in all patients; Cu and Zn levels were decreased in 31 (22 %) and 28 (19.9 %) patients, respectively. In the group of patients with low Cu levels, 18 (58.1 %) were CPKU and in the group with low Zn levels, 13 (46.4 %) were CPKU; all of them received Phe free formula. Plasma tHcy levels were elevated only in two PKU patients, both of them displayed B12 levels in the normal range (362 pg/mL and 237 pg/mL, respectively), whereas its levels were decreased in 58 patients (41.1 %), mainly in patients with an adequate adherence to treatment (50 patients, 86.2 %) and with lower Phe tolerance (44 patients, 75.9 %). hsCRP was elevated in 4 patients (2.84 %), all of them were PKU patients who were on dietary treatment, above 18 years of age and with overweight/obesity. Met levels were in the normal range for all the patients (26.96 ± 4.2 μmol/L).

Children and adults patients with PKU had higher systolic blood pressure (114.9 ± 14.4 vs. 105.5 ± 12.03 mmHg; p = 0.0438) than patients with MHPA. Although diastolic blood pressure was also higher in the PKU group compared with the MHPA group (69.3 ± 13.65 vs. 65.7 ± 10.49 mmHg), this difference did not reach statistical
The significance. It is worth mentioning that a statistically significant quadratic correlation was observed between median Phe and systolic BP ($p = 6.42 \times 10^{-5}$), and a linear correlation between median Phe and diastolic BP ($p = 5.65 \times 10^{-4}$), both in patients below and above 18 years of age (Fig. 2).

With regard to body mass index (BMI), 47 patients (33.33 %) did not have an adequate BMI Z-score, which had a value below the lower threshold in 10 patients (7.1 %) and above the upper threshold in 37 patients (26.24 %) [25 (67.6 %) were overweight and 12 (32.4 %) were obese]. Waist circumference (WC) was above the recommended threshold in 52 (36.9 %) patients [27 (51.9 %) of them above the 95th percentile]. Arm circumference (AC) was elevated in 26 (18.4 %) patients [11 (42.3 %) of them above the 95th percentile]. The percentage of patients with elevated BMI Z-score and WC was significantly higher in the group of PKU patients compared with the MHPA group [34 (91.9 %) vs. 3 (8.1 %), $p = 0.005$ for BMI Z-score; and 45 (86.5 %) vs. 7 (13.5 %), $p = 0.007$ for WC]. When age of patients was considered, we observed that patients who had an elevated BMI Z-score were all above 18 years of age [37 (100 %) vs. 0 (0 %), $p = 4.57 \times 10^{-23}$], and that a higher percentage of patients above 18 years of age had WC above the recommended thresholds [34 (65.4 %) vs. 18 (34.6 %), $p = 5.63 \times 10^{-7}$], with only 2 (6.25 %) patients diagnosed with PKU. Furthermore, BMI Z-score, AC and WC were also statistically significantly higher in patients with good metabolic control compared to patients with poor metabolic control: 26 (70.3 %) vs. 11 (29.7 %) ($p = 0.011$) for BMI Z-score; 39 (76.9 %) vs. 13 (23.1 %) ($p = 0.048$) for AC; and 19 (75 %) vs. 4 (25 %) ($p = 0.035$) for WC (Fig. 3).

Biochemical parameters such as TC, TGC, LDL-C, tHcy and BP were higher in overweight or obese patients with PKU. By contrast, HDL-C was lower in these patients (Fig. 4). Levels of hsCRP were elevated in 4 out of the 55 analysed patients (7.27 %), all of them with overweight/obesity. No statistically significant differences between the underweight and the normal nutritional status groups were found, except from WC, which was lower in the group of patients with underweight and below 18 years of age ($p = 0.007$). With regard to 6R-BH$_4$ treatment, statistically significant differences in HDL-C levels were observed between the 6R-BH$_4$-treated and the non-treated group (mean: 60.65 ± 14.04 vs. 50.28 ± 11.61 mg/dL, $p = 0.0367$).

### Discussion

Reduction of animal origin lipids and cholesterol intake, which is one of the main characteristics of the PKU diet, could be considered to be the definition of non-atherogenic diet [12]. To support this hypothesis, previously published studies have suggested a similar or even improved lipid profile in PKU children compared to healthy controls [25]. Only few studies have explored lipid profile or other coronary heart disease-related parameters in PKU patients. Taking into account that PKU patients require a lifelong treatment, we consider that special attention and further investigations are required.

Our findings did not show significant differences in TGC levels between the PKU and MHPA groups of

### Table 1

|          | MHPA | PKU |
|----------|------|-----|
| Number patients | 41   | 100 |
| Gender – Male    | 20   | 47  |
| Gender – Female  | 21   | 53  |
| Average Age      | 9y 7 m | 17y 10 m |
| Under 18 years   | 35   | 57  |
| zBMI – obese + overweight | 3    | 34  |
| zBMI – normal    | 33   | 61  |
| zBMI – underweight | 5    | 5   |
| WC - obese + overweight | 7    | 45  |
| WC - normal      | 30   | 50  |
| WC - underweight | 4    | 5   |
| AC - obese + overweight | 5    | 21  |
| AC - normal      | 21   | 27  |
| AC - underweight | 4    | 15  |
| Early Diagnostic | 40   | 85  |
| BH4 treatment    | 0    | 17  |
| Adequated Diet adherence | 40   | 80  |
| Phe Tol (mg/day) | 1889.6 ± 831.9 | 481.1 ± 376.3 |
| Phe median (μmol/L) | 238.6 ± 93.2 | 397.3 ± 281.9 |
| Total Cholesterol (mg/dL) | 164.2 ± 21.9 | 149.9 ± 31.5 |
| HDL (mg/dL)      | 55.8 ± 12.6 | 49.8 ± 11.9 |
| LDL (mg/dL)      | 92.1 ± 17.2 | 82.1 ± 24.7 |
| ApoA (mg/dL)     | 160.7 ± 26.4 | 144.1 ± 25.9 |
| ApoB (mg/dL)     | 75.5 ± 17.6 | 65.9 ± 19.1 |
| LDL/ApoB         | 1.26 ± 0.16 | 1.22 ± 0.19 |
| Triglycerids (mg/dL) | 79.2 ± 36.2 | 91.7 ± 45.7 |
| Homocystein (μmol/L) | 5.9 ± 2.4 | 5.9 ± 3.3 |
| Systolic BP (mmHg) | 105.5 ± 12 | 114.9 ± 14.4 |
| Diastolic BP (mmHg) | 65.7 ± 10.5 | 69.3 ± 13.7 |
| B12 (pg/mL)      | 584.9 ± 205.6 | 664.5 ± 333.6 |
| Zinc (μg/dL)     | 82.4 ± 33.1 | 81.2 ± 21.5 |
| Copper (μg/dL)   | 86 ± 22.5 | 78.4 ± 21.3 |
| Zinc/Copper      | 1.01 ± 0.46 | 1.11 ± 0.45 |
Table 2: Number of patients with hyperphenylalaninaemia with altered biochemical concentrations of lipid profile and other related parameters

| Parameter                        | TC (<120 mg/dL) | TC (>200 mg/dL) | TGC (>100 mg/dL below 10 years of age >130 mg/dL above 10 years of age) | HDL-C (<30 mg/dL) | LDL-C (>130 mg/dL) | ApoA1 (<115 mg/dL) | ApoB (>110 mg/dL) | thCy (<5 μmol/L) | thCy. (>15 μmol/L) | Zn (<65 μg/dL) | Cu (>140 μg/dL) | Cu (<65 μg/dL) | B12 (>1900 pg/mL) | hsCRP (>1.1 mg/dL) |
|----------------------------------|-----------------|-----------------|------------------------------------------------------------------------|-------------------|-------------------|-------------------|-------------------|------------------|-------------------|----------------|---------------|---------------|-----------------|------------------|
| Total over patients N (%)       | 19 (13.47)      | 6 (4.25)        | 26 (18.44)                                                              | 2 (1.42)          | 17 (12.06)        | 4 (2.84)          | 6 (4.25)          | 4 (2.84)         | 58 (41.13)        | 2 (1.42)       | 28 (19.86)    | 31 (21.98)    | 3 (2.13)         | 2 (1.42)         | 5 (3.55)         |
| Age (below 18 years of age) N (%)| 14 (73.68)      | 4 (66.67)       | 10 (38.46)                                                              | 1 (50)            | 9 (52.94)         | 1 (25)            | 6 (100)           | 2 (50)           | 50 (86.2)        | 0 (0)          | 23 (82.14)    | 17 (54.84)    | 0 (0)           | 0 (0)           | 0 (0)           |
| Gender (Male) N (%)              | 12 (63.16)      | 3 (50)          | 9 (34.62)                                                               | 0 (0)             | 10 (58.82)        | 1 (25)            | 4 (66.67)         | 2 (50)           | 26 (44.83)        | 2 (100)        | 10 (35.71)    | 12 (38.7)     | 0 (0)           | 0 (0)           | 1 (20)           |
| PKU patients N (%)               | 19 (100)        | 2 (33.33)       | 21 (80.77)                                                              | 2 (100)           | 14 (82.35)        | 3 (75)            | 5 (83.33)         | 2 (50)           | 42 (72.41)        | 2 (100)        | 19 (67.86)    | 26 (83.87)    | 1 (33.33)       | 2 (100)         | 5 (100)          |
| 6R-BH4 therapy N (%)             | 1 (5.26)        | 0 (0)           | 0 (0)                                                                   | 1 (50)            | 0 (0)             | 0 (0)             | 1 (16.67)         | 0 (0)            | 9 (15.52)         | 0 (0)          | 3 (10.71)     | 4 (12.9)      | 0 (0)           | 0 (0)           | 2 (40)           |
| Adherence to treatment (adequate) | 16 (84.21)      | 6 (100)         | 22 (84.62)                                                              | 1 (50)            | 14 (82.35)        | 3 (75)            | 5 (83.33)         | 4 (100)          | 50 (86.2)         | 1 (50)         | 26 (92.86)    | 26 (83.87)    | 3 (100)         | 2 (100)         | 4 (80)           |
| Phe tolerance (under 500 mg/day) | 18 (94.73)      | 3 (50)          | 22 (84.62)                                                              | 2 (100)           | 13 (76.47)        | 2 (50)            | 5 (83.33)         | 3 (75)           | 24 (41.38)        | 0 (0)          | 8 (28.57)     | 22 (70.97)    | 1 (33.33)       | 0 (0)           | 3 (60)           |

*p-values were obtained using Fisher’s exact test and adjusted by Benjamini-Hochberg’s correction to determine statistically significant differences between patients with deficient micronutrient concentrations and patients in the normal range according to: age (below/above 18 years of age), gender (male/female), diagnosis (PKU / MHPA), 6R-BH4 therapy (yes/no), adherence to dietary treatment (adequate/inadequate) and Phe tolerance (below/above 500 mg/day). Statistically significant differences are shown in the Table (p < 0.05). N number of patients, % percentage of patients, TC total cholesterol, TGC triglycerides, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ApoA1 apolipoprotein A, ApoB apolipoprotein B, thCy total homocysteine, Zn Zinc, Cu Cupper, B12 vitamin B12, hsCRP high sensitivity C-Reactive Protein, PKU phenylketonuria, MHPA mild hyperphenylalaninaemia, Phe phenylalanine.
Levels of total cholesterol (TC) in PKU children with good metabolic control have been assessed in few studies and their results have been inconclusive. Whereas in some of these studies have reported that PKU children on diet displayed lower TC levels compared with healthy controls [12, 26]; in one particular study there was no difference in TC levels between PKU and healthy children [13] and in another study TC levels were higher in patients with PKU [27]. In this present study, we showed that plasma TC levels were lower in the group of PKU patients than in the MHPA group. It should be pointed out that serum and tissue cholesterol concentrations depend on both a vegetarian diet, whose main sources of lipid are olive oil and cream cheese, and on cholesterogenesis [26, 28]. Furthermore, there are several regulatory mechanisms which contribute to cholesterol homeostasis. Although in this study we have only analyzed the blood lipid profile of patients with PKU, it is worth mentioning that an in vivo study, in which experimental hyperphenylalaninemia was induced in an animal model, demonstrated that there was an inhibition of two of the main regulatory enzymes of brain and liver cholesterogenesis: 3-hydroxy-3-methylglutaryl-CoA reductase and mevalonate-5-pyrophosphate decarboxylase [29]; and therefore a reduced cholesterol synthesis in the brain may indicate an association between impaired myelination and mental retardation in patients with PKU.

In contrast with other studies, which did not observe differences in plasma HDL levels in PKU children compared to controls [30–32], we found that HDL-C and ApoA levels were statistically significantly lower in PKU patients. However, LDL-C and ApoB levels were statistically significantly lower in the group of PKU patients, which is an indicator of low atherogenic risk. In addition, LDL-C/ApoB ratio was higher in PKU patients who had good dietary compliance. In this regard, it is worth mentioning that Campos et al.’s study [33] suggested that a high LDL-C/ApoB ratio usually correlates with the presence of larger and less atherogenic LDL particles, which are less susceptible to oxidative damage than small LDL particles. No clinical data of ischemic disease or other cardiovascular findings were observed in our patients, although it should be pointed out that only nine of them were between 40 and 50 years of age.

It has been previously reported that high serum Cu and low serum Zn concentrations were significantly associated with an increased mortality rate from all cardiovascular diseases and from coronary heart disease...
in particular [34]. In our study, we observed that only three patients had high Cu levels and 28 (19.9%) of our patients had low serum Zn levels. Furthermore, a study in a rat animal model showed that low Cu levels were associated with the presence of larger LDLs and high serum CT, since this metal modulates the enzymatic activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase, which is involved in cholesterol biosynthesis control [35].

Consistent with a previously published study [6], our data confirmed decreased plasma tHcy levels in PKU patients who have a good dietary compliance; and this was observed with methionine levels in the normal range for all the ages, including adult patients. In contrast, Schulpis et al.' study observed that PKU patients on strict diet had moderate hyperhomocysteinaemia, which was probably due to the fact that these patients displayed low levels of vitamin B₁₂ and folate, both essentials in Hcy metabolism [36].

Since it has been suggested that CRP levels could be considered to be an early endothelial dysfunction biomarker [37], we measured hsCRP, an inflammatory biomarker. We found elevated levels of hsCRP in 4 PKU adult patients with overweight/obesity.

Based on the fact that high blood pressure in adolescence or young adulthood is strongly related to later risk of stroke or coronary heart disease, independently of blood pressure in mid-life [30], in our present study, all patients displayed a statistically significant quadratic correlation between median Phe and systolic blood pressure.
and a statistically significant linear correlation between median Phe and diastolic blood pressure. It should be pointed out that only few studies have shown low diastolic blood pressure in patients with PKU on dietary treatment [14, 30]. This may be due to the fact that the evolution period was short and that studies on blood pressure in adults PKU are very scarce.

As far as overweight and obesity is concerned, there are several reports which suggested a clear tendency towards overweight and obesity in patients with PKU [32, 38–40], according to their BMI values. In this regard, we observed in our cohort that BMI Z-score and WC were higher in the group of PKU patients compared to the MHPA group. In fact, the AC, which is a strong indicator of caloric and protein sources because it reflects fat content and muscle, was elevated in 16.31% of our PKU patients. Although a control group was not included in our study, when our results were compared to the nutritional status in the Spanish general population [41], we observed that the BMI Z-score is higher in our patients. Indeed, 37% of our patients above 18 years of age had an elevated BMI Z-score, whereas in Spain it is a 26.7% of the general population. In this line of research, Mazola et al. [42] showed similar BMI in patients with PKU compared with controls, but only 48% of the patients in that study had good metabolic control. In our study, although a control group without PKU or MHPA was not included, we found that the BMI Z-score was statistically significantly higher in patients with good metabolic control compared to patients with poor metabolic control. This fact may be associated with protein substitutes intake and commercial low-Phe products, which most of them have a high caloric content.

Moreover, BMI Z-score significantly correlated with several cardiovascular risk factors such as elevated levels of TGC, tHcy and high BP. On the other hand, it was observed that patients under 6R-BH₄ treatment, and therefore on a less restricted diet, had a clear tendency towards normal values of these parameters.
Conclusions

Our findings demonstrated that PKU patients, who had good adherence to their diet, are not at risk of developing atherosclerosis because the levels of their lipids, lipoproteins and apolipoproteins indicated a less atherogenic profile. Nevertheless, a high percentage of patients with low Phe tolerance and good dietary compliance were overweight or obese and showed elevated levels of atherogenic biochemical markers in addition to high tHcy levels and BP. These findings highlight the importance that in PKU patients it is safe to avoid overweight and obesity and advisable to monitor blood pressure, homocysteine and inflammatory biomarkers levels as well as others potential cardiovascular risk factors.

Additional file

Additional file 1: Characteristics of Hyperphenylalaninaemia patients with altered values of the biochemical parameters studied. (DOCX 85 kb)

Acknowledgements

We thank all patients and their families for kindly participating in the study.

Funding

Article-processing charge was covered by the Fundación Ramón Domínguez-C012.

Availability of data and material

Data supporting the findings of this study are included in this published article and its supplementary information files. The datasets generated during and/or analysed during the current study are available from the corresponding author upon reasonable request.

Authors’ contributions

MLC designed the study, supervised the analysis of the data, reviewed the publications included in the systematic review and drafted the manuscript. IV, LA-E, RL and AH participated in its design and coordination of the study and helped draft the manuscript. PSP and AFM reviewed the publications included in the systematic review, analysed the data and drafted the manuscript. IR analysed the statistical study and drafted the manuscript. ML helped draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study protocol was approved by the Research Ethics Committee of Santiago-Lugo (2015/393). Written informed consent was obtained from parents or legal guardians of children (below 16 years of age) and patients included.

Fig. 4 Biochemical parameters of lipid profile, homocysteine and blood pressure in patients with phenylketonuria classified according to their body mass index. Box-plot diagrams showing A) Triglycerides (mg/dL), B) Total Cholesterol (mg/dL), C) HDL-Cholesterol (mg/dL), D) Homocysteine (μmol/L), E) Systolic BP (mmHg) and F) Diastolic BP (mmHg). The X-axis indicates the underweight, normal and overweight & obese groups in our patients with phenylketonuria. Box-plots show median values (solid horizontal line); 25th and 75th percentiles (box); minimum and maximum values (bars); outliers (open circles). The * indicates the statistical significant differences: *p < 0.05, **p < 0.01 and ***p < 0.001, using the statistical tests described in the Methods Section. BMI: body mass index; HDL-cholesterol: high-density lipoprotein cholesterol; BP: blood pressure.
Author details
1Unit of Diagnosis and Treatment of Congenital Metabolic Diseases. S. Neonatology, Department of Pediatrics, Hospital Clínico Universitario de Santiago, CIBERER, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, 15706 Santiago de Compostela, A Coruña, Spain. 2Unit of Metabolopathies, Hospital Universitario La Fe, Bulevar sur s/n, 46021 Valencia, Spain. 3Unit of Metabolism. Cruces University Hospital, Biocruces Health Research Institute, GCV-CIBER de Enfermedades Raras (CIBERER), Plaza de Cruces s/n, 48903 Barakaldo, Vizcaya, Spain. 4Unit of Gastroenterology and Nutrition, Department of Pediatrics, Hospital Clínico Universitario de Santiago, Health Research Institute of Santiago de Compostela, A Coruña, Spain. 5Unit of Diagnosis and Treatment of Congenital Metabolic Diseases, Department of Internal Medicine, Universidad de Santiago, Santiago de Compostela, Spain.

Received: 25 May 2016 Accepted: 31 August 2016

Published online: 09 September 2016

References
1. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376:1417–27. 2. Martínez-Pardo M, Marchante C, Dalmau J, Pérez M, Bellón C. Protocolo de diagnóstico, tratamiento y seguimiento de las hiperfenilalaninemias. An Esp Pediatr. 1998;114:13–18. 3. Okano Y, Nagasaka H. Optimal serum phenylalanine for adult patients with phenylketonuria. Mol Genet Metab. 2013;110(Suppl):S42–30. 4. Mira A, Bóveda MD, Leis MR, Mera A, Aldámiz-Echevarría L, Fernández-Lozano JR, Fraga JM, Couce ML. Risk factors for developing mineral bone disease in phenylketonuric patients. Mol Genet Metab. 2013;108:149–54. 5. Giovannini M, Verduci E, Salvatici E, Paci S, Riva E. Phenylketonuria: nutritional advances and challenges. Nutr Metab. 2012;9:1–7. 6. Huerler M, Simma B, Mayr D, Möslinger D, Mühle A, Schmid I, Uhlner H, Bodamer OA. Free asymmetric dimethylarginine (ADMA) is low in children and adolescent with classical PKU. J Inherit Metab Dis. 2012;35:817–21. 7. Crujeiras V, Aldámiz-Echevarría L, Dalmau J, Vitoria I, Andrade F, Roca I, Leis R, Fernández-Marmiesse A, Couce ML. Vitamin and mineral status in patients with hyperphenylalaninemia. Mol Genet Metab. 2015;115(4):145–50. 8. Evans S, Daly A, MacDonald J, Preece MA, Santra S, Djavari F, Calzado R, MacDonald J, Preece MA, Santra S, Djavari F, Calzado R, MacDonald J, Preece MA, Santra S, Djavari F, Calzado R, MacDonald J, Preece MA, Santra S, Djavari F. Nutritional aspects of phenylketonuria: correlation between blood lipids and immunoglobulins A, M and in a phenylketonuric paediatric population on diet therapy. Dev Brain Dysfunc. 1995;5:168–71. 9. Verduci E, Banderas G, Moretti F, Lassandro C, Cefalo R, Radielli G, Salvatici E, Giovannini M. Diet in children with phenylketonuria and risk of cardiovascular disease: A narrative overview. Nutr Metab Cardiovasc Dis. 2016;26:71–7. 10. Castillo M, Zafría MF, García-Peregrín E. Inhibition of brain and liver 3-hydroxy-3-methylglutaryl-CoA reductase and mevalonate-5-pyrophosphate decarboxylase in experimental hyperphenylalaninemia. Neurochem Res. 1988;13:551–5. 11. Darnton-Hill I, Nishida C, James WPT. A life course approach to diet, nutrition and the prevention of chronic diseases. Public Health Nutr. 2004;7:101–21. 12. Rocha JC, van Spronsen FJ, Almeida MF, Soares G, Queis M, Rojas J. Neutrometabolismo y la hipertensión. J Hypertens. 2013;31:1281–3. 13. Schulpi KH, Harpur D, Wilfand BS, Young JM. Parenteral reductase activity. J Nutr Biochem. 1990;1:27–33. 14. Aldámiz-Echevarría L, Bueno MA, Couce ML, Lages S, Dalmau J, Vitoria I, Andrade F, Blasco J, Alcalde C, Gil D, García MC, González-Lamuño D, Ruiz M, Peña-Quintana L, Ruiz MA, González D, Sánchez-Valverde F. Anthropometric characteristics and nutrition in a cohort of PAH-deficient patients. Clin Nutr. 2014;33:702–17. 15. Campos H, Genest J, Blijlevens E, Mc Namara JR, Jenner JL, Ordovas JM. Low density lipoprotein size and coronary artery disease. Arterioscler Thromb. 1992;12:187–95. 16. Reunanen A, Knekt P, Marnierl M, Mäki J, Maetel J, Aromaa A. Serum calcium, magnesium, copper and zinc and risk of cardiovascular death. Eur J Clin Nutr. 1996;50:431–7. 17. Yount NY, Mc Namara DJ, Al Ottman AA, Lei KJ. The effect of copper deficiency on rat hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. J Nutr Biochem. 1990;1:27–33. 18. Schulpi KH, Karcas GA, Papakonstantinou E. Homocysteine and other vascular risk factors in patients with phenylketonuria on diet. Acta Paediatr. 2002;91:1–5.

Phenylketonuria Scientific Review Conference: state of the science and future research needs. Mol Genet Metab. 2014;112:87–122. 19. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. National Heart, Lung and Blood Institute, Bethesda, Maryland. Pediatrics. 2004;114:555–6. 20. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens. 2013;31:1281–357. 21. Acosta PB, Yannicelli SY, R. Singh R, Mofidi S, Steiner R, De Vincenzi E, Jurek E, Bernstein L, Gleason S, Chetty M, Rouse B. Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy. J Am Diet Assoc. 2003;103:1167–73. 22. WHO, Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1–452.

WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards based on length/height, weight and age. Acta Pediatr. 2006;95:576–85.

10. Lammardo AM, Robert M, Rocha JC, van Rijn M, Ahnring K, Bélanger-Quintana A, MacDonald A, Dokoupil K, Gokmen-Ozeln H, Lammardo AM, Goyens P, Feillet F. Micronutrient supplementation in phenylketonuria. Mol Genet Metab. 2013;110(Suppl):S6. 11. Tojo Sierra R, Leis Trabazo R. Estudio Galinut. Valores Estandar de Galicia. Santiago de Compostela: Universidad de Santiago de Compostela; 1999.

24. R Core Team. R: A language and environment for statistical computing. R project.org/.

25. Schulpi KH, Scarpalezou A. Triglycerides, cholesterol HDL, LDL, and VLDL cholesterol in serum of phenylketonuric children under dietary control. Clin Pediatr. 1989;28:466–9.

26. Colome C, Artuchi R, Lambuscini N, Cambra FJ, Campistol J, Vilaseca MA. Is there a relationship between plasma phenylalanine and cholesterol in phenylketonuric patients under dietary treatment? Clin Biochem. 2001;33:373–6.

27. Giovannini M, Agostini C, Bellu R, Ghiglioni D, Guffe B, Biascchi G, Riva E. Nutritional aspects of phenylketonuria: correlation between blood lipids and immunoglobulins A, M and in a phenylketonuric paediatric population on diet therapy. Dev Brain Dysfunc. 1995;5:168–71.
37. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of c-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–65.
38. Dokoupil K, Gokmen-Ozel H, Lammardo AM, Motzfeldt K, Robert M, Rocha JC, van Rijn M, Ahring K, Belanger-Quintana A, Mac Donald A. Optimising growth in phenylketonuria: current state of the clinical evidence base. Clin Nutr. 2012;31:16–21.
39. Giovannini M, Verduci E, Salvatici E, Fiori L, Riva E. Phenylketonuria: dietary and therapeutic challenges. J Inherit Metab Dis. 2006;30:145–52.
40. Scaglioni S, Verduci E, Fiori L, Lammardo AM, Rossi S, Radaelli G, Riva E, Giovannini M. Body mass index rebound and overweight at 8 years of age in hyperphenylalaninaemic children. Acta Paediatr. 2004;93:596–600.
41. Overweight and obesity and their impact on health. Global Status Report on noncommunicable diseases 2014. World Health Organization (WHO). http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf.
42. Mazzola PN, Nalin T, Castro K, van Rijn M, Derks TG, Perry ID, Mainieri AS, Schwartz IV. Analysis of body composition and nutritional status in Brazilian phenylketonuria patients. Mol Genet Metab Rep. 2016;6:16–20.